Dr. Gershony grew up in Toronto, Canada and attended the University of Toronto where he graduated from medical school at age 23. He continued his training in internal medicine and general cardiology at the University of Toronto where he also served as Chief Medical Resident. Dr. Gershony continued his training in interventional cardiology, serving a fellowship at Emory University in Atlanta under the auspices of Dr. Andreas Grüntzig, the inventor of coronary and peripheral angioplasty. From 1993-1997, Dr. Gershony was Director of the Cardiac Catheterization Laboratories and Interventional Cardiology at the University of California, Davis, Medical Center. Since 1999 he has practiced interventional cardiology at John Muir Cardiovascular Institute in the San Francisco Bay Area where he is currently the Director of Cardiovascular Research, Education and Technology, and has established a successful Transcatheter Aortic Valve Replacement (TAVR) program. Dr. Gershony’s research interests include novel devices for complex coronary and peripheral angioplasty, percutaneous valve therapies and local drug-delivery to prevent restenosis. He has participated in numerous multi-center clinical trials as a Principal Investigator. Dr. Gershony is board certified in general cardiology and interventional cardiology and is a Fellow of the American College of Cardiology, the Royal College of Physicians, the American Heart Association and the Society for Cardiovascular Angiography and Interventions. Dr. Gershony has authored over 100 manuscripts and abstracts in the field of cardiology and is a regularly invited faculty lecturer to the preeminent U.S. and international interventional cardiology meetings.
Dr. Gershony was the Founder of Vascular Solutions (VASC) which had a successful IPO in 2000 and was acquired by Teleflex (TFX) for $1B in 2017. He served as Chief Medical Officer and a member of the Board of Directors from 1996-2002. Dr. Gershony was the principal inventor of the Duett™ Vascular Sealing Device manufactured by Vascular Solutions.
Dr. Gershony was also the Co-Founder, Board member and Chief Medical Officer of AngioScore, a medical device company devoted to developing unique scoring balloon catheters to address a variety of important clinical needs during coronary, peripheral and valvular interventional procedures. He was a member of the senior management team from 2003 until AngioScore’s successful acquisition by Spectranetics (SPNC) for $300M in 2014.
Dr. Gershony has served on the adjunct faculty of the Stanford Biodesign Innovation Program. He also completed an Executive Program in finance and accounting (FANFE) at the Stanford Graduate School of Business in 2007.
Dr. Gershony is the author of 11 issued medical device patents. He has been a member of the scientific advisory board or a consultant to numerous medical device companies and venture capitalists in the Bay Area and elsewhere.
Dr. Gershony is an active early stage MedTech company investor and mentor, a member of Life Science Angels Medical Device and Digital Health Committee, and a member of the Band of Angels. He is a current Board member of ValFix Medical, Crystalline Medical and RAM Medical, and a Scientific Advisory Board member of AtaCor Medical and Paladin Medical.
Dr. Gershony is a frequent speaker or panelist at early stage MedTed investor conferences.
Gary is attending / has attended:
Venture Summit | West 2020
Venture Summit Virtual Connect | Global
Venture Summit Virtual Connect 3
VSVC West 2021
Venture Summit Virtual Connect | Global 21